Healing · 80mg × 10 vials
BPC builds new blood supply into broken tissue, TB-500 tells cells to migrate into damage sites and quiets the inflammation around them, GHK-Cu drives collagen and elastin synthesis with copper as the structural cofactor, and KPV closes the loop by suppressing the inflammatory pathway that drove the damage in the first place.
KLOW is a four-peptide co-formulated blend in a single 80 mg vial: BPC-157 (~11 mg), TB-500 (~11 mg), GHK-Cu (~50 mg, the dominant component by mass), and KPV (~8 mg, roughly 10% of the blend). The four ingredients hit healing and anti-aging from four distinct mechanistic pathways that do not overlap, which is the whole rationale for stacking them rather than choosing one. BPC-157 upregulates VEGFR2 and drives local angiogenesis (new capillary formation) into damaged tissue plus restores tight junction integrity in gut lining. TB-500 sequesters G-actin monomers to enable cell migration into wound beds, upregulates VEGF systemically, and dampens TNF-alpha / NF-kB pro-inflammatory signaling. GHK-Cu delivers a copper(II) cofactor for lysyl oxidase (collagen/elastin crosslinking) and superoxide dismutase (antioxidant defense), and at the transcriptome level modulates expression of ~4,000 human genes back toward a younger profile per the 2010 Broad Institute Connectivity Map analysis. KPV is a tripeptide off the alpha-MSH C-terminus (Lys-Pro-Val) that binds melanocortin receptors (primarily MC1R/MC5R) to shut down NF-kB and cytokine cascades, with the strongest preclinical data in colitis, IBD, and skin-inflammation models.
In plain language: BPC builds new blood supply into broken tissue, TB-500 tells cells to migrate into damage sites and quiets the inflammation around them, GHK-Cu drives collagen and elastin synthesis with copper as the structural cofactor, and KPV closes the loop by suppressing the inflammatory pathway that drove the damage in the first place. Tissue repair (BPC + TB-500), cosmetic/structural renewal (GHK-Cu), and anti-inflammatory coverage (KPV) layered in one injection. There is no head-to-head clinical trial of the four-way blend, the mechanistic rationale is the sum of each component's documented effects and there is no documented receptor competition or pathway antagonism among the four.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This is the Jordan default protocol for first-time KLOW users. 80 mg vial + 2 ml BAC = 40 mg/ml, so 2 mg = 0.05 ml = 5 IU on a U-100 syringe. One vial lasts ~40 days at this dose, a 10-vial kit covers ~13 months of continuous research (well past two full cycles). Beginner-friendly across goals: skin/hair, joint maintenance, gut, general anti-aging.
Standard working dose band for active joint/tendon injury layered with aesthetic goals, post-procedure recovery (microneedling, laser, surgical scars), or chronic skin inflammation (rosacea, eczema, post-acne scarring). Split dosing favored for active injury phase to keep BPC blood levels steadier given its 4 hr plasma half-life. At 4 mg/day, one vial lasts 20 days, a kit covers ~6.5 months.
Aggressive protocol for major post-surgical recovery, chronic stubborn joint issues (rotator cuff, Achilles, golfer's elbow, plantar fasciitis), autoimmune-adjacent skin or gut conditions, or post-rapid-weight-loss skin laxity at high body mass loss. At 5 mg/day, one vial lasts 16 days, a kit covers ~5 months. Almost always layered with one of: Reta (post-loss skin), CJC+Ipa (training recovery), NAD+ (long-COVID / Lyme), depending on customer profile. Local SubQ near target tissue is community-favored for site-specific work (knee, shoulder, scalp, face).
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
foundational BPC-157 mechanism + animal evidence
Read study ↗PubMedChang et al, J Appl Physiol 2011 - BPC 157 VEGFR2 angiogenesisangiogenic mechanism
Read study ↗PubMedGoldstein AL, Hannappel E, Kleinman HK - Thymosin beta-4 actin-sequestering protein review, Trends Mol Med 2005TB-500 foundational mechanism
Read study ↗PubMedBock-Marquette I et al - Thymosin beta-4 activates ILK and promotes cardiac repair, Nature 2004TB-500 cardiac repair seminal paper
Read study ↗PubMedPickart L - GHK and DNA: Resetting the Human Genome to Health, 2014GHK-Cu Connectivity Map analysis, 4,000+ gene modulation
Read study ↗PubMedGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (PMC4508379)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/) - GHK-Cu skin/wound mechanism review
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Injection site irritation: most-reported sensation across PP customers, mild redness or tenderness for a few hours, mostly driven by the GHK-Cu component (copper peptide). Rotates out with site rotation.
Cloudy reconstitution: not a side effect but the #1 customer support touchpoint. Caused by rapid mixing or cold-shock against the copper ion. Resolves on gentle swirling and warming to room temp.
Mild fatigue or "off" feeling first 5-10 days: tracks with the TB-500 community signal (first-week loading drag). Attributed to the body diverting resources into repair response. Resolves week 2.
"Old injury flare-up" sensation: some users describe transient achiness in previously-healed injury sites during the first 2-4 weeks. Anecdotal, tracks with TB-500's "the body remembering and re-healing" community frame.
Mild headache or light dizziness: rare, low single-digit anecdotal reports, usually first injection or two, settles.
Skin tingling near injection site: occasional, attributed to GHK-Cu component, transient.
Route: SubQ (community default), IM tolerated, local SubQ near target tissue for site-specific use (joint-adjacent for tendon work, abdominal for gut, near scalp/face for skin and hair)
Injection site: Abdomen or outer thigh, rotate sites. For local-target use (knee, shoulder, scalp, face), inject SubQ into closest skin to the area, not intra-articular.
Storage: Refrigerated, 28 days after reconstitution. Lyophilized vial keeps room temp for shipping windows, refrigerate on arrival. Solution will be pale blue from the GHK-Cu copper ion, this is normal. Cloudiness on reconstitution can occur from rapid mixing or cold-shock, swirl gently and let warm to room temp, if it persists past 10 minutes the vial is suspect.
Notes: Reconstitution variability is the #1 customer support issue with KLOW because of the GHK-Cu copper component. Tell every customer up front: mix slowly, swirl don't shake, room temp, blue tint is normal. The four peptides are pre-mixed at the manufacturer and stable in lyophilized form. Do NOT add vitamin C or glutathione to the same syringe (copper-ascorbate / copper-reducing-agent interaction); injection-day separation from those compounds is fine. Some users add a daily oral zinc supplement during KLOW cycles to balance the copper load, this is community convention, not documented requirement. Light-sensitive once reconstituted, keep in the original vial in the fridge.